kynurenine has been researched along with Nervous System Disorders in 26 studies
Kynurenine: A metabolite of the essential amino acid tryptophan metabolized via the tryptophan-kynurenine pathway.
kynurenine : A ketone that is alanine in which one of the methyl hydrogens is substituted by a 2-aminobenzoyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "There were statistically significant increases of CSF neopterin, kynurenine, quinolinic acid and kynurenine/tryptophan ratio (KYN/TRP) in the inflammation group compared to all control groups (all p < 0." | 8.31 | CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation. ( Andrews, PI; Antony, J; Ardern-Holmes, S; Bandodkar, S; Chung, J; Dale, RC; Farrar, MA; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Jones, HF; Kandula, T; Keating, BA; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pillai, SC; Sampaio, H; Tantsis, E; Troedson, C; Webster, R; Yan, J, 2023) |
| "Kynurenine is a metabolite of the tryptophan-nicotine-amide-adenine-dinucleotide pathway." | 6.38 | [Kynurenine and its metabolites in nervous system diseases]. ( Schwab, F; Vécsei, L, 1992) |
| "There were statistically significant increases of CSF neopterin, kynurenine, quinolinic acid and kynurenine/tryptophan ratio (KYN/TRP) in the inflammation group compared to all control groups (all p < 0." | 4.31 | CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation. ( Andrews, PI; Antony, J; Ardern-Holmes, S; Bandodkar, S; Chung, J; Dale, RC; Farrar, MA; Gill, D; Guillemin, GJ; Guller, A; Gupta, S; Han, VX; Heng, B; Jones, HF; Kandula, T; Keating, BA; Kothur, K; Menezes, MP; Mohammad, S; Patel, S; Pillai, SC; Sampaio, H; Tantsis, E; Troedson, C; Webster, R; Yan, J, 2023) |
| "Neuroinflammation is one of the most frequently studied topics of neurosciences as it is a common feature in almost all neurological disorders." | 2.72 | Neurological Infection, Kynurenine Pathway, and Parasitic Infection by ( Argolo, DS; Costa, MFD; Costa, SL; Del'Arco, AE; Guillemin, G; Pinheiro, AM, 2021) |
| " quinolinic acid, an excitotoxin and N-Methyl-d-Aspartate (NMDA) receptor agonist), while in turn enhancing the bioavailability of the neuroprotective metabolites such as kynurenic acid." | 2.55 | Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. ( Brew, BJ; Guillemin, GJ; Jacobs, K; Lennon, MJ; Lim, CK; Lovelace, MD; Sundaram, G; Varney, B, 2017) |
| "Probenecid (PROB) has been widely used for long time for different clinical purposes, from gout treatment to designs as a coadjutant for antibiotic agents." | 2.49 | Probenecid: an emerging tool for neuroprotection. ( Colín-González, AL; Santamaría, A, 2013) |
| "Kynurenine (KYN) is an intermediate in the pathway of the metabolism of tryptophan to nicotinic acid." | 2.43 | Role of kynurenines in the central and peripheral nervous systems. ( Németh, H; Toldi, J; Vécsei, L, 2005) |
| "Quinolinic acid is an agonist at the N-methyl-D-aspartate sensitive subtype of glutamate receptors in the brain, while kynurenic acid is an antagonist and, thus, a potential neuroprotectant." | 2.41 | Endogenous neurotoxins from tryptophan. ( Stone, TW, 2001) |
| "Kynurenine is a metabolite of the tryptophan-nicotine-amide-adenine-dinucleotide pathway." | 2.38 | [Kynurenine and its metabolites in nervous system diseases]. ( Schwab, F; Vécsei, L, 1992) |
| "The kynurenine pathway has received increasing attention as its connection to inflammation, the immune system and neurological conditions has become more apparent." | 1.42 | What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics? ( Davis, I; Liu, A, 2015) |
| "Quinolinic acid (QUIN) is an endogenous N-methyl-D-aspartate receptor agonist synthesized from L-tryptophan via the kynurenine pathway and thereby has the potential of mediating N-methyl-D-aspartate neuronal damage and dysfunction." | 1.28 | Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. ( Crowley, JS; Davis, LE; Demitrack, MA; Der, M; Dilling, LA; Elia, J; Heyes, MP; Kruesi, MJ; Lackner, A; Saito, K, 1992) |
| "In patients with encephalopathy, serum QUIN was elevated with corresponding increments in CSF QUIN." | 1.28 | Neuroactive kynurenines in Lyme borreliosis. ( Halperin, JJ; Heyes, MP, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (23.08) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 5 (19.23) | 2.80 |
| Authors | Studies |
|---|---|
| Pires, AS | 1 |
| Sundaram, G | 2 |
| Heng, B | 2 |
| Krishnamurthy, S | 1 |
| Brew, BJ | 2 |
| Guillemin, GJ | 3 |
| Del'Arco, AE | 1 |
| Argolo, DS | 1 |
| Guillemin, G | 2 |
| Costa, MFD | 1 |
| Costa, SL | 1 |
| Pinheiro, AM | 1 |
| Kozieł, K | 1 |
| Urbanska, EM | 1 |
| Yan, J | 1 |
| Kothur, K | 1 |
| Mohammad, S | 1 |
| Chung, J | 1 |
| Patel, S | 1 |
| Jones, HF | 1 |
| Keating, BA | 1 |
| Han, VX | 1 |
| Webster, R | 1 |
| Ardern-Holmes, S | 1 |
| Antony, J | 1 |
| Menezes, MP | 1 |
| Tantsis, E | 1 |
| Gill, D | 1 |
| Gupta, S | 1 |
| Kandula, T | 1 |
| Sampaio, H | 1 |
| Farrar, MA | 1 |
| Troedson, C | 1 |
| Andrews, PI | 1 |
| Pillai, SC | 1 |
| Guller, A | 1 |
| Bandodkar, S | 1 |
| Dale, RC | 1 |
| Huang, YS | 1 |
| Ogbechi, J | 1 |
| Clanchy, FI | 1 |
| Williams, RO | 1 |
| Stone, TW | 3 |
| Colín-González, AL | 2 |
| Santamaría, A | 2 |
| Davis, I | 1 |
| Liu, A | 1 |
| Yeung, AW | 1 |
| Terentis, AC | 1 |
| King, NJ | 1 |
| Thomas, SR | 1 |
| O'Farrell, K | 1 |
| Harkin, A | 1 |
| Fujigaki, H | 1 |
| Yamamoto, Y | 1 |
| Saito, K | 2 |
| Lovelace, MD | 1 |
| Varney, B | 1 |
| Lennon, MJ | 1 |
| Lim, CK | 1 |
| Jacobs, K | 1 |
| Schwarcz, R | 2 |
| Aguilera, G | 1 |
| Oxenkrug, GF | 1 |
| Vécsei, L | 3 |
| Bruno, JP | 1 |
| Muchowski, PJ | 1 |
| Wu, HQ | 1 |
| Németh, H | 1 |
| Toldi, J | 1 |
| Hafizi, S | 1 |
| Favaron, E | 1 |
| Ting, KK | 1 |
| Brew, B | 1 |
| Gasse, T | 1 |
| Murr, C | 1 |
| Meyersbach, P | 1 |
| Schmutzhard, E | 1 |
| Wachter, H | 1 |
| Fuchs, D | 1 |
| Heyes, MP | 3 |
| Schwab, F | 1 |
| Crowley, JS | 1 |
| Davis, LE | 1 |
| Demitrack, MA | 1 |
| Der, M | 1 |
| Dilling, LA | 1 |
| Elia, J | 1 |
| Kruesi, MJ | 1 |
| Lackner, A | 1 |
| Halperin, JJ | 1 |
| Freese, A | 1 |
| Swartz, KJ | 1 |
| During, MJ | 1 |
| Martin, JB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigating Brain Abnormalities in People With Knee Osteoarthritis Using MRI: a Nociplastic Pain Mechanism Based Assessment[NCT05986513] | 66 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | |||
| Effects of 3-month Probiotic Mix Supplementation (L. Helveticus R-0052, B. Longum R-0175) on Gut Microbiota and Metabolome, Endocannabinoid and Immune Systems Activation, Along With Symptoms of Fatigue in Professional Dancers[NCT05567653] | 60 participants (Anticipated) | Interventional | 2022-09-21 | Recruiting | |||
| Pilot Study Aimed to Determine the Optimal Design for the UCLA/Danone Probiotic Intervention Study Related to Stress[NCT05026333] | 100 participants (Actual) | Interventional | 2021-06-25 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
20 reviews available for kynurenine and Nervous System Disorders
| Article | Year |
|---|---|
Recent advances in clinical trials targeting the kynurenine pathway.
Topics: Humans; Kynurenine; Male; Nervous System Diseases; Quinolinic Acid; Tryptophan | 2022 |
Neurological Infection, Kynurenine Pathway, and Parasitic Infection by
Topics: Animals; Humans; Inflammation; Kynurenine; Neospora; Nervous System Diseases; Parasitic Diseases; Si | 2021 |
Kynurenine Pathway in Diabetes Mellitus-Novel Pharmacological Target?
Topics: Animals; Brain; Diabetes Mellitus; Diabetic Retinopathy; Humans; Kynurenine; Nervous System Diseases | 2023 |
IDO and Kynurenine Metabolites in Peripheral and CNS Disorders.
Topics: Animals; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Nervous System Diseases | 2020 |
Probenecid: an emerging tool for neuroprotection.
Topics: Animals; Brain; Drug Interactions; Humans; Kynurenine; Models, Neurological; Nervous System Diseases | 2013 |
Role of indoleamine 2,3-dioxygenase in health and disease.
Topics: Animals; Bacterial Infections; Catalysis; Gene Expression Regulation, Enzymologic; Humans; Indoleami | 2015 |
Stress-related regulation of the kynurenine pathway: Relevance to neuropsychiatric and degenerative disorders.
Topics: Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Nervous System Diseases; Stress, Psych | 2017 |
L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences.
Topics: Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Nervous System Diseases; Tryptophan | 2017 |
Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases.
Topics: Animals; Humans; Kynurenine; Metabolic Networks and Pathways; Nervous System Diseases; Tryptophan | 2017 |
The kynurenine pathway and the brain: Challenges, controversies and promises.
Topics: Animals; Brain; Humans; Kynurenine; Metabolic Networks and Pathways; Nervous System Diseases | 2017 |
Cannabinoids: Glutamatergic Transmission and Kynurenines.
Topics: Animals; Brain; Cannabinoids; Humans; Kynurenine; Nervous System Diseases; Quinolinic Acid | 2016 |
Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism.
Topics: Aging; Animals; Endocrine System Diseases; Humans; Kynurenine; Metabolic Syndrome; Nervous System Di | 2010 |
Kynurenines in the mammalian brain: when physiology meets pathology.
Topics: Animals; Brain; Humans; Kynurenine; Nervous System Diseases; Signal Transduction | 2012 |
Role of kynurenines in the central and peripheral nervous systems.
Topics: Animals; Central Nervous System; Humans; Kynurenine; Nervous System Diseases; Peripheral Nervous Sys | 2005 |
Interferon-induced depression: mechanisms and management.
Topics: Cyclooxygenase 2; Depressive Disorder; Female; Humans; Hypothalamo-Hypophyseal System; Interferon-al | 2007 |
The involvement of astrocytes and kynurenine pathway in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Astrocytes; Brain Chemistry; Electrophysiology; Humans; Kynurenine; Nerv | 2007 |
The kynurenine pathway and neurologic disease. Therapeutic strategies.
Topics: 3-Hydroxyanthranilic Acid; Animals; Gerbillinae; Guinea Pigs; Humans; Kynurenine; Macrophage Activat | 1996 |
Endogenous neurotoxins from tryptophan.
Topics: Animals; Humans; Kynurenine; Nervous System Diseases; Neurotoxins; Quinolinic Acid; Tryptophan | 2001 |
[Kynurenine and its metabolites in nervous system diseases].
Topics: Humans; Kynurenic Acid; Kynurenine; Nervous System Diseases; Quinolinic Acid; Quinolinic Acids | 1992 |
Kynurenine metabolites of tryptophan: implications for neurologic diseases.
Topics: Animals; Brain; Humans; Kynurenine; Nervous System Diseases; Tryptophan | 1990 |
6 other studies available for kynurenine and Nervous System Disorders
| Article | Year |
|---|---|
CSF neopterin, quinolinic acid and kynurenine/tryptophan ratio are biomarkers of active neuroinflammation.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Humans; Infant; Inflammation; Kynurenine; Leukocyto | 2023 |
What is the tryptophan kynurenine pathway and why is it important to neurotherapeutics?
Topics: Animals; Humans; Kynurenine; Nervous System Diseases; Signal Transduction; Tryptophan | 2015 |
Kynurenines and the nervous system: therapeutic perspectives.
Topics: Animals; Drug Delivery Systems; Humans; Kynurenine; Nervous System; Nervous System Diseases | 2012 |
Neopterin production and tryptophan degradation in acute Lyme neuroborreliosis versus late Lyme encephalopathy.
Topics: Acute Disease; Adult; Aged; Biopterins; Borrelia Infections; Chromatography, High Pressure Liquid; F | 1994 |
Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease.
Topics: Aged; Animals; Brain Diseases; Encephalitis; Female; HIV Infections; Humans; Kynurenic Acid; Kynuren | 1992 |
Neuroactive kynurenines in Lyme borreliosis.
Topics: Brain Diseases; Humans; Kynurenine; Lyme Disease; Lymphokines; Multiple Sclerosis; Nervous System Di | 1992 |